Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy

被引:44
作者
Mygind, H
Thulstrup, AM
Pedersen, L
Larsen, H
机构
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Gynecol & Obstet, DK-8000 Aarhus, Denmark
[3] Aalborg Hosp, Aalborg, Denmark
[4] Randers Cent Hosp, Dept Paediat, Randers, Denmark
关键词
epidemiology; malformations; pregnancy; topical corticosteroid;
D O I
10.1034/j.1600-0412.2002.810308.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. Topical corticosteroids are frequently used drugs, but little is known of the exposure during pregnancy and birth outcome. Methods. In a population-based follow-up study restricted to primigravida women, we examined the risk of low birth weight, malformations and other birth outcomes following pregnancy upon exposure to topical corticosteroids. We compared the offspring of 363 women exposed to topical corticosteroids during pregnancy with 9263 controls, who received no prescriptions at all. Results. The prevalence of malformations was 2.9% among 170 infants exposed during the first trimester and 3.6% among the controls. Adjusted odds ratios for low birth weight, malformations and preterm delivery among women receiving weak/medium strong corticosteroids were 0.7 (95% Cl 0.17-2.85), 0.93 (95% Cl 0.23-3.80) and 1.04 (95% CI 0.56-1.92), respectively, and adjusted odds ratios for strong/very strong corticosteroids were 1.23 (95% CI 0.45-3.37) 0.56 (95% Cl 0.14-2.28) and 0.99 (95% CI 0.54-1.84), respectively. Conclusions. The study showed no increased risk of low birth weight, malformations or preterm delivery in the offspring of women exposed to topical corticosteroid during pregnancy.
引用
收藏
页码:234 / 239
页数:6
相关论文
共 27 条
[1]  
Andersen TF, 1999, DAN MED BULL, V46, P263
[2]   COMPARATIVE TERATOGENICITY OF SELECTED GLUCOCORTICOIDS APPLIED OCULARLY IN MICE [J].
BALLARD, PD ;
HEARNEY, EF ;
SMITH, MB .
TERATOLOGY, 1977, 16 (02) :175-180
[3]  
BRIGGS GG, 1998, DRUGS PREGNANCY LACT, P1050
[4]  
BRIGGS GG, 1998, DRUGS PREGNANCY LACT, P96
[5]  
Czeizel AE, 1997, TERATOLOGY, V56, P335, DOI 10.1002/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO
[6]  
2-W
[7]  
Gaist D, 1997, DAN MED BULL, V44, P445
[8]  
HARRIS JWS, 1956, LANCET, V1, P1045
[9]   PREGNANCY OUTCOME IN RENAL-ALLOGRAFT RECIPIENTS IN NORWAY - THE IMPORTANCE OF IMMUNOSUPPRESSIVE DRUG REGIMEN AND HEALTH-STATUS BEFORE PREGNANCY [J].
HAUGEN, G ;
FAUCHALD, P ;
SODAL, G ;
LEIVESTAD, T ;
MOE, N .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1994, 73 (07) :541-546
[10]  
Heinonen O, 1977, BIRTH DEFECTS DRUGS